{"id":32335,"date":"2025-05-29T17:29:48","date_gmt":"2025-05-29T11:59:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32335"},"modified":"2025-05-29T17:30:02","modified_gmt":"2025-05-29T12:00:02","slug":"medtech-news-for-olympus-abbott-sensome","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome","title":{"rendered":"Olympus Gains FDA Clearance for EDOF\u2122 Imaging Endoscopes; FDA Approves Abbott\u2019s Tendyne\u2122 Device for Minimally Invasive Mitral Valve Replacement; New Study Validates Exact Sciences&#8217; Oncodetect\u2122 for Enhanced MRD Detection in Stage II-IV Colorectal Cancer; Sensome Completes First-in-Human Trial Enrollment for Lung Cancer Detection System; J&amp;J MedTech Introduces SOUNDSTAR CRYSTAL\u2122 to US Market with Breakthrough 2D Imaging Quality; Terumo Launches ROADSAVER\u2122 Carotid Stent System to Improve Outcomes in Carotid Artery Stenosis"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e1eea7dd08f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e1eea7dd08f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\/#Olympus_Secured_FDA_Clearance_for_Cutting-Edge_EDOF%E2%84%A2_Imaging_Endoscopes_Redefining_Visibility_with_Sharper_Blur-Free_Views\" >Olympus Secured FDA Clearance for Cutting-Edge EDOF\u2122 Imaging Endoscopes, Redefining Visibility with Sharper, Blur-Free Views<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\/#Abbott_Gained_FDA_Approval_for_Groundbreaking_Tendyne%E2%84%A2_Device_Pioneering_Minimally_Invasive_Mitral_Valve_Replacement\" >Abbott Gained FDA Approval for Groundbreaking Tendyne\u2122 Device, Pioneering Minimally Invasive Mitral Valve Replacement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\/#Exact_Sciences_Validated_Oncodetect%E2%84%A2_Test_in_New_Study_Advancing_MRD_Detection_and_Recurrence_Prediction_in_Stage_II-IV_Colorectal_Cancer\" >Exact Sciences Validated Oncodetect\u2122 Test in New Study, Advancing MRD Detection and Recurrence Prediction in Stage II-IV Colorectal Cancer&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\/#Sensome_Completed_Enrollment_in_First-in-Human_Study_of_In_Situ_Tumor_Detection_System_for_Lung_Cancer_Marking_Key_Milestone_in_Early_Diagnosis_Innovation\" >Sensome Completed Enrollment in First-in-Human Study of In Situ Tumor Detection System for Lung Cancer, Marking Key Milestone in Early Diagnosis Innovation&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\/#Johnson_Johnson_MedTech_Launched_SOUNDSTAR_CRYSTAL%E2%84%A2_in_the_US_Setting_New_Standard_for_2D_Intracardiac_Image_Clarity\" >Johnson &amp; Johnson MedTech Launched SOUNDSTAR CRYSTAL\u2122 in the US, Setting New Standard for 2D Intracardiac Image Clarity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\/#Terumo_Corporation_Released_ROADSAVER%E2%84%A2_Carotid_Stent_System_Commercially_Enhancing_Clinical_Outcomes_in_Carotid_Artery_Stenting_to_Addresses_Carotid_Artery_Stenosis\" >Terumo Corporation Released ROADSAVER\u2122 Carotid Stent System Commercially, Enhancing Clinical Outcomes in Carotid Artery Stenting to Addresses Carotid Artery Stenosis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-olympus-secured-fda-clearance-for-cutting-edge-edof-imaging-endoscopes-redefining-visibility-with-sharper-blur-free-views\"><span class=\"ez-toc-section\" id=\"Olympus_Secured_FDA_Clearance_for_Cutting-Edge_EDOF%E2%84%A2_Imaging_Endoscopes_Redefining_Visibility_with_Sharper_Blur-Free_Views\"><\/span><strong>Olympus Secured FDA Clearance for Cutting-Edge EDOF\u2122 Imaging Endoscopes, Redefining Visibility with Sharper, Blur-Free Views<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 27, 2025, Olympus Corporation, a global leader in medical technology and endoscopic imaging, announced that it received FDA 510(k) clearance for its next-generation EZ1500 series endoscopes. The newly approved models, including the GIF-EZ1500 gastroscope and the CF-EZ1500DL\/I colonoscope, are equipped with proprietary Extended Depth of Field (EDOF\u2122) technology and represent a significant advancement in the company\u2019s EVIS X1\u2122 endoscopy platform.<\/p>\n\n\n\n<p>The integration of EDOF\u2122 technology allows physicians to obtain high-resolution, sharply focused images across an extended depth range. This innovation enhances visualization of the gastrointestinal (GI) mucosa, supporting improved lesion detection and diagnostic confidence during endoscopic procedures. By maintaining the entire lesion in clear focus, EDOF\u2122 has the potential to contribute to earlier and more accurate diagnoses.<\/p>\n\n\n\n<p><em>\u201cAs a leading global MedTech company, Olympus remains committed to providing advanced options to help physicians offer their patients the best care possible,\u201d said Kurt Heine, Senior Vice President and General Manager for Gastrointestinal Solutions at Olympus Corporation. \u201cOur goal is to elevate the standard of endoscopy, and Extended Depth of Field (EDOF) technology represents Olympus\u2019 most advanced scope technology to help physicians drive the best clinical outcomes for advancing gastrointestinal procedures.\u201d<\/em><\/p>\n\n\n\n<p>Olympus Corporation received FDA 510(k) clearance for its EZ1500 series endoscopes, marking a significant advancement in endoscopic imaging and procedural efficiency. The GIF-EZ1500 gastroscope and CF-EZ1500DL\/I colonoscope are the first Olympus endoscopes to feature Extended Depth of Field (EDOF\u2122) technology as part of the EVIS X1\u2122 endoscopy platform. EDOF\u2122 technology leverages a dual-prism optical system to split incoming light into two separate beams, one near-focused and one far-focused. These beams are projected simultaneously onto a single image sensor and then merged into a unified, sharply focused image. This approach enables physicians to maintain crisp, detailed views across a broad range of depths, minimizing image blurring and enhancing mucosal inspection.<\/p>\n\n\n\n<p>The EZ1500 series also introduced the new ErgoGrip<sup>TM<\/sup> control section, designed with user ergonomics in mind. The control section was approximately 10% lighter than the previous 190 series and features a rounded, easy-to-maneuver handle with accessible angulation knobs optimized for a broad range of users, including those with smaller hands. When connected to the EVIS X1 CV-1500 video system center, the EZ1500 series scopes were compatible with Olympus\u2019 suite of advanced imaging technologies, including Texture and Color Enhancement Imaging (TXI\u2122), Red Dichromatic Imaging (RDI\u2122), and Narrow Band Imaging\u2122 (NBI\u2122), which further enhances visualization and clinical decision-making.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/endoscopes-market\"><strong>Endoscopes Market Report<\/strong><\/a>\u201d, the global endoscopes market was valued at <strong>USD 12.95 billion<\/strong> in 2023, growing at a <strong>CAGR of 6.05%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 18.32 billion<\/strong> by 2030. The increase in demand for endoscopes is primarily attributed to the increasing prevalence of chronic diseases that require the use of endoscopes for the diagnosis, such as some gastrointestinal diseases like irritable bowel syndrome (IBD), gastroesophageal reflux disease (GERD), peptic ulcer disease, and Crohn&#8217;s disease, increase in the number of geriatric population who are more prone to chronic ailments, increasing awareness and demand of minimally invasive surgeries and no blood loss surgery, and rise in technological advancements in endoscopes like image magnification, high-definition optical systems and digital imaging are anticipated to bolster the market, thereby contributing to the growth of the endoscopes market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbott-gained-fda-approval-for-groundbreaking-tendyne-device-pioneering-minimally-invasive-mitral-valve-replacement\"><span class=\"ez-toc-section\" id=\"Abbott_Gained_FDA_Approval_for_Groundbreaking_Tendyne%E2%84%A2_Device_Pioneering_Minimally_Invasive_Mitral_Valve_Replacement\"><\/span><strong>Abbott Gained FDA Approval for Groundbreaking Tendyne\u2122 Device, Pioneering Minimally Invasive Mitral Valve Replacement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 27, 2025, Abbott announced the U.S. Food and Drug Administration (FDA) approval of its Tendyne\u2122 Transcatheter Mitral Valve Replacement (TMVR) system, a breakthrough minimally invasive therapy for patients with mitral valve disease who are not candidates for conventional surgery. This approval marks a major advancement in structural heart care, providing a critical new option for treating patients with severe mitral annular calcification (MAC), a complex condition characterized by calcium buildup in the mitral valve annulus that impairs valve function.<\/p>\n\n\n\n<p>The Tendyne system is designed to replace a dysfunctional mitral valve through a transcatheter approach, eliminating the need for open-heart surgery. This innovation provides a life-saving alternative for high-risk patients with severe MAC, a population with limited treatment options and historically poor outcomes. With this approval, Tendyne becomes the first and only TMVR device specifically indicated in the U.S. for the treatment of patients with mitral valve dysfunction due to MAC, further strengthening Abbott\u2019s leadership in the fast-growing market for minimally invasive structural heart therapies. The system complements Abbott\u2019s comprehensive portfolio, which includes technologies for mitral and tricuspid valve repair and replacement.<\/p>\n\n\n\n<p><em>&#8220;Mitral annular calcification stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupt the heart&#8217;s ability to pump blood effectively. These conditions can have a significant impact on a patient&#8217;s quality of life, causing symptoms such as chest pains, shortness of breath and dizziness,&#8221; said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital. &#8220;Unfortunately, patients with MAC can be very difficult to operate on and many are considered too high risk for open-heart surgery due to multiple co-morbidities or other factors. Tendyne bridges a critical treatment gap for these patients and can help reduce the symptoms that can interfere with their lives.&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;Tendyne is a much-needed addition to our comprehensive U.S. structural heart portfolio that offers less invasive treatment options for a range of heart diseases,&#8221; said Sandra Lesenfants, senior vice president of Abbott&#8217;s structural heart business. &#8220;This approval builds on our more than two decades of mitral valve leadership that includes developing first-of-their-kind devices that truly change \u2013 and save \u2013 people&#8217;s lives.&#8221;<\/em><\/p>\n\n\n\n<p>The Abbott Tendyne\u2122 TMVR system features a unique, self-expanding valve design available in multiple sizes, enabling it to accommodate a wide range of patient anatomies. Delivered through a small chest incision, the valve is advanced into the heart and can be fully repositioned or retrieved during the procedure, helping ensure optimal placement and patient outcomes. This FDA approval highlights Abbott\u2019s continued commitment to advancing minimally invasive, catheter-based heart therapies that improve outcomes, reduce surgical risk, and expand access for patients with limited treatment options.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/transcatheter-mitral-valve-repair-devices-market\"><strong>Transcatheter Mitral Valve Repair Devices Market Report<\/strong><\/a>\u201d, the global transcatheter mitral valve repair devices market was valued at <strong>USD 1,197.06 million<\/strong> in 2023, growing at a <strong>CAGR of 14.95%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 2,756.71 million<\/strong> by 2030. The transcatheter mitral valve repair devices market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle &amp; lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-exact-sciences-validated-oncodetect-test-in-new-study-advancing-mrd-detection-and-recurrence-prediction-in-stage-ii-iv-colorectal-cancer-nbsp\"><span class=\"ez-toc-section\" id=\"Exact_Sciences_Validated_Oncodetect%E2%84%A2_Test_in_New_Study_Advancing_MRD_Detection_and_Recurrence_Prediction_in_Stage_II-IV_Colorectal_Cancer\"><\/span><strong>Exact Sciences Validated Oncodetect\u2122 Test in New Study, Advancing MRD Detection and Recurrence Prediction in Stage II-IV Colorectal Cancer&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 28, 2025, Exact Sciences Corp., a leader in cancer diagnostics, announced new clinical validation data for its tumor-informed molecular residual disease (MRD) test, Oncodetect\u2122, to be presented at the 2025 ASCO Annual Meeting. Findings from the Beta-CORRECT study, part of the GALAXY cohort, confirm the test\u2019s ability to predict cancer recurrence in stage II-IV colorectal cancer, reinforcing its value in guiding treatment and surveillance decisions. Looking ahead, Exact Sciences will launch a next-generation version of Oncodetect\u2122 in 2026, powered by the Broad Institute\u2019s MAESTRO technology. This advanced test will track up to 5,000 patient-specific variants and detect circulating tumor DNA (ctDNA) at levels below 1 part per million, offering even greater sensitivity. The updated test will be available to both new and existing customers.<\/p>\n\n\n\n<p>At the 2025 ASCO Annual Meeting, Exact Sciences shared new results from its largest molecular residual disease (MRD) clinical study to date, Beta-CORRECT. The data confirmed that the Oncodetect\u2122 test accurately predicted recurrence in stage III colorectal cancer, consistent with previous findings from the Alpha-CORRECT study, and further extended this association to stages II and IV. In a cohort of over 400 patients, those who tested ctDNA-positive after treatment or during surveillance had a 24- and 37-fold increased risk of recurrence, respectively. By tracking ctDNA levels over time, Oncodetect supports more informed treatment and surveillance decisions, helping physicians personalize care throughout the patient journey.<\/p>\n\n\n\n<p><em>\u201cWe launched the Oncodetect test to give clinicians and patients a powerful tool for detecting cancer recurrence earlier and with greater precision\u2014progress that\u2019s already being realized,\u201d said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. \u201cWe continue to innovate and look forward to introducing the next iteration of the Oncodetect test, which leverages whole-genome sequencing and proprietary technology developed in collaboration with the Broad Institute to enhance sensitivity and expand clinical utility.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cThe precision and sensitivity seen in the next generation test reflect deep scientific collaboration and a shared commitment to advancing MRD technology,\u201d said Viktor Adalsteinsson, Ph.D., Director, Gerstner Center for Cancer Diagnostics at the Broad Institute. \u201cThis approach to innovation will continue to raise the bar for recurrence monitoring, treatment response assessment, and, ultimately, patient outcomes.\u201d<\/em><\/p>\n\n\n\n<p>Exact Sciences is developing a next-generation molecular residual disease (MRD) test designed to monitor up to 5,000 patient-specific variants with a limit of detection below 1 part per million. Currently, in validation across multiple solid tumor types, this highly sensitive test will support broad clinical applications and scalable cancer monitoring. The test is powered by MAESTRO, a proprietary whole-genome sequencing technology exclusively licensed from the Broad Institute. MAESTRO enables accurate detection of low-frequency ctDNA mutations across thousands of sites while reducing sequencing depth, delivering high performance at a lower cost.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/in-vitro-diagnostics-market\"><strong>In-Vitro Diagnostics Market Report<\/strong><\/a>\u201d, the global in-vitro diagnostics market was valued at <strong>USD 71.01 billion<\/strong> in 2024, growing at a <strong>CAGR of 4.71%<\/strong> during the forecast period from 2025 to 2032, to reach <strong>USD 93.60 billion<\/strong> by 2032. The in vitro diagnostics market is estimated to register positive revenue growth owing to factors such as the rising prevalence of various infectious diseases, such as COVID-19, the growing prevalence of various cancers, increasing cases of hematological diseases, and increasing product development activities with respect to in vitro diagnostics, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sensome-completed-enrollment-in-first-in-human-study-of-in-situ-tumor-detection-system-for-lung-cancer-marking-key-milestone-in-early-diagnosis-innovation-nbsp\"><span class=\"ez-toc-section\" id=\"Sensome_Completed_Enrollment_in_First-in-Human_Study_of_In_Situ_Tumor_Detection_System_for_Lung_Cancer_Marking_Key_Milestone_in_Early_Diagnosis_Innovation\"><\/span><strong>Sensome Completed Enrollment in First-in-Human Study of In Situ Tumor Detection System for Lung Cancer, Marking Key Milestone in Early Diagnosis Innovation&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 27, 2025, Sensome, a leader in microsensing technology for real-time, intraoperative tissue analysis, announced the completion of patient enrollment in its groundbreaking INSPECT clinical study. This first-in-human, multi-center, single-arm trial is evaluating Sensome\u2019s novel tumor detection system, developed to identify cancerous tissue in situ during transbronchial biopsies of endobronchial and peripheral lung tumors.<\/p>\n\n\n\n<p>The INSPECT study enrolled 27 patients, aimed to assess the ability of the technology to accurately identify lung lesion tissue and differentiate cancerous from healthy tissue in real time. Sensome\u2019s proprietary microsensing platform is designed to provide immediate feedback to bronchoscopists, confirming needle placement within a tumor without relying on imaging modalities that often lack the resolution to clearly detect malignant tissue.<\/p>\n\n\n\n<p><em>\u201cWe are very encouraged by our experience using the Sensome tumor detection technology. It has significant potential to make lung biopsies more efficient, and our treatment of lung cancer \u2013 the leading cause of cancer deaths globally \u2013 more effective,\u201d said Amir Hanna, MD, Interventional Pulmonologist, Coordinating Investigator of the INSPECT study, and Principal Investigator at Lannelongue Hospital, France.<\/em><\/p>\n\n\n\n<p><em>\u201cWe found the technology easy to understand and integrate into our bronchoscopy workflow, as the microsensor is integrated into a wire delivered through the biopsy needle, similar to the current stylet we typically use,\u201d added David Fielding, MD, Associate Professor, Director of Thoracic Medicine, and Principal Investigator of the study at Royal Brisbane and Women\u2019s Hospital in Australia.<\/em><\/p>\n\n\n\n<p>Sensome\u2019s proprietary sensor technology leverages electrical impedance spectroscopy to analyze tissue characteristics in a full 360\u00b0 view around the sensor tip. This miniaturized sensing platform is compact enough to be integrated into a medical device introduced through a standard biopsy needle, enabling real-time, in situ tissue assessment. By guiding physicians to the optimal biopsy site with greater precision, Sensome\u2019s tool-in-lesion system may help accelerate lung cancer diagnosis and reduce the need for repeat procedures. The ability to identify tumor tissue on the spot has the potential to significantly improve procedural accuracy and streamline the care pathway for patients with suspected lung cancer.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-glucose-monitoring-systems-market\"><strong>Cancer Diagnostics Market Report<\/strong><\/a>,\u201d the global cancer diagnostics market was valued at <strong>USD 125.13 billion<\/strong> in 2023, growing at a <strong>CAGR of 9.43%<\/strong> during the forecast period from 2024 to 2030, to reach <strong>USD 214.88 billion<\/strong> by 2030. The increase in demand for cancer Diagnostics products and services is predominantly attributed to the spike in cancer cases reported worldwide. In addition, growing manufacturers&#8217; focus on developing advanced cancer diagnostic products, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among patients, and others are anticipated to drive the global cancer diagnostics market during the forthcoming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-amp-johnson-medtech-launched-soundstar-crystal-in-the-us-setting-new-standard-for-2d-intracardiac-image-clarity\"><span class=\"ez-toc-section\" id=\"Johnson_Johnson_MedTech_Launched_SOUNDSTAR_CRYSTAL%E2%84%A2_in_the_US_Setting_New_Standard_for_2D_Intracardiac_Image_Clarity\"><\/span><strong>Johnson &amp; Johnson MedTech Launched SOUNDSTAR CRYSTAL\u2122 in the US, Setting New Standard for 2D Intracardiac Image Clarity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 21, 2025, Johnson &amp; Johnson MedTech, a global leader in the treatment of cardiac arrhythmias, announced the U.S. launch of the SOUNDSTAR CRYSTAL<sup>TM<\/sup> Ultrasound Catheter, a next-generation device designed to enhance intracardiac echocardiography (ICE) imaging during cardiac ablation procedures. SOUNDSTAR CRYSTAL<sup>TM<\/sup> delivers improved 2D image quality compared to existing ICE catheters, providing electrophysiologists with clearer visualization to support precision in complex procedures. Fully integrated with the CARTO\u2122 3 Mapping System, the catheter works seamlessly with the CARTOSOUND\u2122 FAM module, which leverages artificial intelligence to streamline mapping and improve procedural efficiency.<\/p>\n\n\n\n<p>The CARTOSOUND\u2122 FAM module utilizes a novel AI algorithm to automatically generate a 3D anatomical map of the left atrium based on ICE images collected during a rotational sweep of the catheter in the right atrium. This AI-driven approach enhances workflow integration and simplifies left atrial anatomy reconstruction, enabling faster and more informed decision-making for electrophysiologists.<\/p>\n\n\n\n<p><em>\u201cWe are proud to advance our legacy in integrated ultrasound catheters with this latest innovation that equips electrophysiologists with the tools they need to promote patient safety and drive effective results,\u201d said Jasmina Brooks, President, Electrophysiology, Johnson &amp; Johnson MedTech. \u201cThe superior image quality, improved catheter maneuverabilityii and stability of the SOUNDSTAR CRYSTAL\u2122 Ultrasound Catheter, along with seamless CARTO\u2122 3 System integrationi can help enable a zero fluoroscopy workflow, enhancing procedure effectiveness and safety for both healthcare professionals and patients they treat.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cDuring the cases I performed with the SOUNDSTAR CRYSTAL\u2122 Ultrasound Catheter, I was impressed by the clear visualization, tissue definition and enhanced far field imaging, and full integration with other platforms. Integration with the CARTO\u2122 3 System provides clear, high-resolution images which simplify the anatomical mapping process and procedure workflow,\u201d said Amin Al-Ahmad, MDx, St. David\u2019s HealthCare, Austin, TX.<\/em><\/p>\n\n\n\n<p>The SOUNDSTAR CRYSTAL\u2122 Ultrasound Catheter is the latest advancement in Johnson &amp; Johnson MedTech\u2019s comprehensive portfolio of ultrasound solutions, designed to support precision and efficiency in cardiac procedures. Featuring an 88-element phased linear array, the catheter delivers exceptional image quality and detailed visualization of complex intracardiac structures, critical for guiding catheter ablation procedures. Seamlessly integrated with the CARTO\u2122 3 System, SOUNDSTAR CRYSTAL\u2122 supports a cohesive, streamlined workflow. Its optimized design offers an ideal balance of stiffness and flexibility, providing electrophysiologists with enhanced control and maneuverability within the heart.<\/p>\n\n\n\n<p>SOUNDSTAR CRYSTAL\u2122 builds on the momentum of recent innovations such as the NUVISION\u2122 Catheter, which brings advanced 4D imaging capabilities to procedures like Left Atrial Appendage Closure (LAAC). Together, these technologies reflect Johnson &amp; Johnson MedTech\u2019s commitment to advancing intracardiac imaging and empowering physicians with tools that drive accuracy, efficiency, and improved patient outcomes.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/intracardiac-echocardiography-devices-market\"><strong>Intracardiac Echocardiography Devices Market Report<\/strong><\/a>\u201d, the global intracardiac echocardiography devices market is estimated to grow at a <strong>CAGR of 5.33%<\/strong> during the forecast period from 2025 to 2032. The demand for intracardiac echocardiography devices is primarily being boosted by the increasing prevalence of arrhythmia, atrial septal defects, and other cardiovascular diseases. Further, the rising figures of elderly patients, rising demand for minimally invasive approaches, increasing lifestyle disorders, and technological innovations pertaining to cardiac-related devices, among others, are thereby contributing to the overall growth of the intracardiac echocardiography devices market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-terumo-corporation-released-roadsaver-carotid-stent-system-commercially-enhancing-clinical-outcomes-in-carotid-artery-stenting-to-addresses-carotid-artery-stenosis\"><span class=\"ez-toc-section\" id=\"Terumo_Corporation_Released_ROADSAVER%E2%84%A2_Carotid_Stent_System_Commercially_Enhancing_Clinical_Outcomes_in_Carotid_Artery_Stenting_to_Addresses_Carotid_Artery_Stenosis\"><\/span><strong>Terumo Corporation Released ROADSAVER\u2122 Carotid Stent System Commercially, Enhancing Clinical Outcomes in Carotid Artery Stenting to Addresses Carotid Artery Stenosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 27, 2025, Terumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of the FDA-approved ROADSAVER\u2122 Carotid Stent System in the United States. This innovative device is indicated for use with the Nanoparasol\u00ae Embolic Protection System and is designed to treat carotid artery stenosis in patients at increased risk of complications from carotid endarterectomy. The ROADSAVER\u2122 Stent System features a unique dual-layer micromesh design, offering the protection of a closed-cell stent with the flexibility and deliverability of an open-cell stent. This hybrid structure is engineered to optimize plaque coverage and reduce the risk of embolic events, while maintaining the conformability needed to navigate complex vascular anatomy.<\/p>\n\n\n\n<p><em>\u201cROADSAVER Stent System is yet another example of our unrelenting pursuit of achieving better outcomes for patients,\u201d said Chris Pearson, Executive Vice President \u2013 US Commercial Operations, Terumo Interventional Systems. \u201cIts rapid delivery and accurate placement drive procedure predictability and efficiency, differentiating it from other carotid artery stents on the market and providing a level of confidence unmatched in the industry.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cAn inner micromesh layer with a pore size four times smaller than any carotid stent, which provides sustained embolic protection, makes the ROADSAVER Stent System a leading technology in the evolution of CAS,\u201d said Michael J. Martinelli, MD, FACC, FSCAI, and Chief Medical Officer, Terumo Medical Corporation. \u201cThis is supported by the results of clinical trials, which demonstrated that using ROADSAVER for symptomatic patients with high-risk lesions is safe and effective, with a low complication rate.\u201d<\/em><\/p>\n\n\n\n<p>The ROADSAVER\u2122 Carotid Stent System is the first and only dual-layer micromesh stent approved for carotid artery stenting (CAS) in the U.S. Its innovative design combines the benefits of a closed-cell stent with excellent plaque coverage and the flexibility of an open-cell stent, ensuring optimal wall apposition even in challenging anatomies. It is uniquely engineered to contain plaque against the vessel wall and prevent plaque protrusion, helping to reduce the risk of distal embolization. ROADSAVER\u2122 is available in a wide range of sizes (5\u201310 mm width; 22\u201347 mm length) and features a 143 cm rapid-exchange shaft for ease of use. Its low-profile 5Fr design improves crossability, and the stent is fully re-sheathable and repositionable, even after 50% deployment, offering greater control during placement.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/carotid-artery-stent-market\"><strong>Carotid Artery Stent Market Report<\/strong><\/a>\u201d, the global carotid artery stents market was valued at <strong>USD 575.76 million <\/strong>in 2023, growing at a <strong>CAGR of 3.21% <\/strong>during the forecast period from 2024 to 2030 to reach <strong>USD 718.25 million<\/strong> by 2030. The demand for carotid artery stents is primarily being boosted by the increasing prevalence of cardiovascular disorders such as stroke, ischemic stroke, and Transient Ischemic Attack (TIA), among others. Additionally, the increasing demand for minimally invasive surgical procedures is another key factor influencing the positive growth of the market. Further, rising technological developments in the domain of stents is also contributing to the overall growth of the carotid artery stents market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Olympus Secured FDA Clearance for Cutting-Edge EDOF\u2122 Imaging Endoscopes, Redefining Visibility with Sharper, Blur-Free Views On May 27, 2025, Olympus Corporation, a global leader in medical technology and endoscopic imaging, announced that it received FDA 510(k) clearance for its next-generation EZ1500 series endoscopes. The newly approved models, including the GIF-EZ1500 gastroscope and the CF-EZ1500DL\/I colonoscope, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32337,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19154,22313,19511,19126,22551,2753,17021,16975],"industry":[17226],"therapeutic_areas":[17242,17228],"class_list":["post-32335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer-diagnostics","tag-carotid-artery-stent","tag-endoscopes","tag-in-vitro-diagnostics-2","tag-intracardiac-echocardiography-devices","tag-medical-device","tag-medical-devices-market","tag-medtech-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Olympus, Abbott, Sensome<\/title>\n<meta name=\"description\" content=\"Olympus\u2019 EDOF\u2122 Imaging Endoscopes; Abbott\u2019s Tendyne\u2122 Device; Exact Sciences\u2019 Oncodetect Test; Johnson &amp; Johnson MedTech\u2019s SOUNDSTAR CRYSTAL\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Olympus, Abbott, Sensome\" \/>\n<meta property=\"og:description\" content=\"Olympus\u2019 EDOF\u2122 Imaging Endoscopes; Abbott\u2019s Tendyne\u2122 Device; Exact Sciences\u2019 Oncodetect Test; Johnson &amp; Johnson MedTech\u2019s SOUNDSTAR CRYSTAL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T11:59:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T12:00:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/29172930\/medtech-news-for-olympus-abbott-sensome.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Olympus, Abbott, Sensome","description":"Olympus\u2019 EDOF\u2122 Imaging Endoscopes; Abbott\u2019s Tendyne\u2122 Device; Exact Sciences\u2019 Oncodetect Test; Johnson & Johnson MedTech\u2019s SOUNDSTAR CRYSTAL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Olympus, Abbott, Sensome","og_description":"Olympus\u2019 EDOF\u2122 Imaging Endoscopes; Abbott\u2019s Tendyne\u2122 Device; Exact Sciences\u2019 Oncodetect Test; Johnson & Johnson MedTech\u2019s SOUNDSTAR CRYSTAL","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-29T11:59:48+00:00","article_modified_time":"2025-05-29T12:00:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/29172930\/medtech-news-for-olympus-abbott-sensome.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome","name":"MedTech News | Olympus, Abbott, Sensome","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/29172930\/medtech-news-for-olympus-abbott-sensome.png","datePublished":"2025-05-29T11:59:48+00:00","dateModified":"2025-05-29T12:00:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Olympus\u2019 EDOF\u2122 Imaging Endoscopes; Abbott\u2019s Tendyne\u2122 Device; Exact Sciences\u2019 Oncodetect Test; Johnson & Johnson MedTech\u2019s SOUNDSTAR CRYSTAL","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-olympus-abbott-sensome#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/29172930\/medtech-news-for-olympus-abbott-sensome.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/29172930\/medtech-news-for-olympus-abbott-sensome.png","width":772,"height":482,"caption":"medtech-news-for-olympus-abbott-sensome"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/29172930\/medtech-news-for-olympus-abbott-sensome-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Carotid Artery Stent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Endoscopes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">In-Vitro Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Intracardiac Echocardiography Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Carotid Artery Stent<\/span>","<span class=\"advgb-post-tax-term\">Endoscopes<\/span>","<span class=\"advgb-post-tax-term\">In-Vitro Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Intracardiac Echocardiography Devices<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on May 29, 2025","modified":"Updated on May 29, 2025"},"absolute_dates_time":{"created":"Posted on May 29, 2025 5:29 pm","modified":"Updated on May 29, 2025 5:30 pm"},"featured_img_caption":"medtech-news-for-olympus-abbott-sensome","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32335"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32335\/revisions"}],"predecessor-version":[{"id":32336,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32335\/revisions\/32336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32337"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32335"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32335"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}